Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395198 | 0.99 | KMT2A (0.75) | KMT2ATSHRL3MBTL1POLBMEN1 | |
| Lithium Ion SCHEMBL395197 | 0.87 | L3MBTL1 (0.63) | KMT2ATSHRL3MBTL1POLBMEN1 | |
| SCHEMBL3921818 | 0.87 | TSHR (0.97) | KMT2ATSHRL3MBTL1POLBMEN1 | |
| SCHEMBL1647757 | 0.86 | POLB (0.88) | KMT2ATSHRL3MBTL1POLBKDM4E | |
| SCHEMBL1708867 | 0.85 | TSHR (1.00) | KMT2ATSHRL3MBTL1POLBMEN1 | |
| SCHEMBL394951 | 0.85 | L3MBTL1 (0.64) | KMT2ATSHRL3MBTL1POLBMEN1 | |
| SCHEMBL6207754 | 0.85 | KMT2A (0.71) | KMT2ATSHRL3MBTL1MEN1KDM4E | |
| SCHEMBL28655730 | 0.84 | POLB (0.65) | KMT2ATSHRL3MBTL1POLBKDM4E | |
| SCHEMBL6207027 | 0.84 | CYP3A4 (0.75) | KMT2ATSHRPOLBMEN1PKM | |
| SCHEMBL28653785 | 0.84 | HSD17B10 (0.77) | KMT2ATSHRL3MBTL1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604025-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130267537-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8367661-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120232092-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. | 2012-09-13 | — | — | US | disclosed |
| US-8202859-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20120088779-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8101620-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1605752-B1 | Sulfonamides for the treatment of congestive heart failure, their compositions and uses. | CYTOKINETICS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110112154-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2011-05-12 | — | — | US | disclosed |
| US-7888373-B2 | Heterocyclic sulfonamides as modulators of cardiac sarcomeres | CYTOKINETICS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7595322-B2 | Heterocyclic sulfonamides as modulators of cardiac sarcomeres | CYTOKINETICS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1605752-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20070078126-A1 | Useful in selective modulation of cardiac sarcomere, for example, by potentiating cardiac myosin; can be used to treat heart failure including CHF, particularly systolic heart failure; 4-[4-chloro-3-(5-phenyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-benzenesulfonyl]-piperazine-1-carboxylic acid ethyl ester | CYTOKINETICS, INCORPORATED | 2007-04-05 | — | — | US | disclosed |
| EP-1605752-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-0994115-B1 | Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof | PFIZER LTD (GB) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004086865-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20030069422-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | DUNN PETER JAMES (GB) | 2003-04-10 | — | — | US | disclosed |
| US-20010009962-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | DUNN PETER JAMES (GB) | 2001-07-26 | — | — | US | disclosed |
| US-6207829-B1 | CYCLIZATION OF A CORRESPONDING PYRAZOLE COMPOUND | PFIZER INC. | 2001-03-27 | — | — | US | disclosed |
| EP-0994115-A2 | Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof | Pfizer Limited (GB) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267537-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | KMT2A 2395/4885TSHR 3581/4885L3MBTL1 2567/4885 |
| US-20010009962-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | UGT2B7, CYP3A7, TOP2B | KMT2A 2876/4885TSHR 4131/4885L3MBTL1 4245/4885 |
| US-20070078126-A1 | Useful in selective modulation of cardiac sarcomere, for example, by potentiating cardiac myosin; can be used to treat heart failure including CHF, particularly systolic heart failure; 4-[4-chloro-3-(5-phenyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-benzenesulfonyl]-piperazine-1-carboxylic acid ethyl ester | MYLK2, MYH2, MYH14 | KMT2A 2721/4885TSHR 3736/4885L3MBTL1 2553/4885 |
| US-20120232092-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | KMT2A 2395/4885TSHR 3581/4885L3MBTL1 2567/4885 |
| US-20110112154-A1 | Compounds, compositions and methods | TNNI3, TNNT2, MYLK2 | KMT2A 3413/4885TSHR 4440/4885L3MBTL1 3432/4885 |
| US-20120088779-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | KMT2A 2395/4885TSHR 3581/4885L3MBTL1 2567/4885 |
| US-20030069422-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | UGT2B7, CYP3A7, TOP2B | KMT2A 2876/4885TSHR 4131/4885L3MBTL1 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.